HIMS

Hims & Hers Health Inc

Add to Watchlist

Advanced Chart

57.650

+0.33(0.576%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

59.940

Open

58.160

VWAP

57.58

Vol

46.35M

Mkt Cap

12.90B

Low

54.300

Amount

2.67B

EV/EBITDA(TTM)

91.16

Total Shares

214.79M

12.58B

EV/OCF(TTM)

37.63

P/S(TTM)

7.79

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

629.82M

+30.9%

586.25M

+46%

551.30M

+74.66%

Estimates Revision

The market is revising Upward the revenue expectations for Hims & Hers Health, Inc. (HIMS) for FY2025, with the revenue forecasts being adjusted by 0.97% over the past three months. During the same period, the stock price has changed by 102.42%.

Revenue Estimates for FY2025

Revise Upward

+0.97%

In Past 3 Month

Stock Price

Go Up

+102.42%

In Past 3 Month

11 Analyst Rating

-30.96% Downside

Wall Street analysts forecast HIMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIMS is 39.80 USD with a low forecast of 25.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

8 Hold

2 Sell

Hold

-30.96% Downside

Current: 57.650

Low

25.00

Averages

39.80

High

68.00

-30.96% Downside

Current: 57.650

Low

25.00

Averages

39.80

High

68.00

Truist

Hold

maintain

$45 -> $48

2025-07-17

Reason

Truist

Price Target

$45 -> $48

2025-07-17

maintain

Hold

Reason

Truist raised the firm's price target on Hims & Hers to $48 from $45 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as "relatively selective", the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.

Morgan Stanley

Craig Hettenbach

Equal Weight

maintain

$40

2025-07-14

Reason

Morgan Stanley

Craig Hettenbach

Price Target

$40

2025-07-14

maintain

Equal Weight

Reason

Morgan Stanley analyst Craig Hettenbach tells investors that the firm's data reveals a year over year decline in monthly Hims & Hers app downloads for the first time, with 5% y/y web traffic growth in June, the weakest since March 2024. The firm says monthly app downloads are now 185,000, falling below the level seen prior to the launch of compounded GLP-1s. Morgan Stanley has an Equal Weight rating and $40 price target on shares of Hims & Hers.

Needham

Buy

Hold

downgrade

2025-06-23

Reason

Needham

Price Target

2025-06-23

downgrade

Buy

Hold

Reason

Needham downgraded Hims & Hers to Hold from Buy.

Citi

Sell

maintain

$30

2025-06-03

Reason

Citi

Price Target

$30

2025-06-03

maintain

Sell

Reason

Citi keeps a Sell rating on Hims & Hers with a $30 price target after the company acquired Zava, a digital health platform with operations in France, the UK, Germany, and Ireland. The platform is substantially similar to Hims & Hers' U.S. business, providing clinical access and prescriptions in key categories such as sexual health, hair loss, weight loss, and dermatology, the analyst tells investors in a research note. Citi finds it interesting that branded weight loss drugs are offered at a significant discount on Zava versus Hims & Hers. The firm believes the acquisition expands Hims & Hers' European footprint while accelerating its personalization strategy.

Citi

Sell

downgrade

$27 -> $25

2025-04-25

Reason

Citi

Price Target

$27 -> $25

2025-04-25

downgrade

Sell

Reason

Citi lowered the firm's price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a "downside 30-day short-term view" on the shares. Citi expects Hims & Hers will reported "another significant beat and raise" quarter, largely driven by GLP-1 strength. However, this is unlikely to drive the stock higher, the analyst tells investors in a research note. Rather, Citi suspects the stock will trade down again on another sequential slowdown in core revenue with concerns around Hims & Hers' personalized GLP-1 strategy, a weakening consumer, and potential pharma tariffs all weighing on investor sentiment.

Truist Securities

Jailendra Singh

Hold

Maintains

$39 → $33

2025-04-10

Reason

Truist Securities

Jailendra Singh

Price Target

$39 → $33

2025-04-10

Maintains

Hold

Reason

Truist analyst Jailendra Singh lowered the firm's price target on Hims & Hers to $33 from $39 and keeps a Hold rating on the shares as part of a broader research note previewing Q1 results in the Healthcare IT industry. The industry is typically shielded from macro uncertainty, but tariffs and concerns around an economic slowdown have created broader market uncertainty, which is never good for a high-beta highly volatile group like HCIT/Digital Health/Payviders, the analyst tells investors in a research note. Truist adds that while HCIT companies may not be directly exposed to new tariffs, several of these companies serve end markets - hospitals, pharma, etc. - which are likely to see either some direct impact on their supply chain costs or could decide to slow down on their investments.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Hims & Hers Health Inc (HIMS.N) is 70.13, compared to its 5-year average forward P/E of -6.53. For a more detailed relative valuation and DCF analysis to assess Hims & Hers Health Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.53

Current PE

70.13

Overvalued PE

43.42

Undervalued PE

-56.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1.81

Current EV/EBITDA

38.50

Overvalued EV/EBITDA

42.30

Undervalued EV/EBITDA

-38.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.33

Current PS

5.23

Overvalued PS

6.04

Undervalued PS

0.61

Financials

Annual

Quarterly

FY2025Q1

YoY :

+110.67%

586.01M

Total Revenue

FY2025Q1

YoY :

+459.41%

57.92M

Operating Profit

FY2025Q1

YoY :

+344.69%

49.49M

Net Income after Tax

FY2025Q1

YoY :

+300.00%

0.20

EPS - Diluted

FY2025Q1

YoY :

+321.31%

50.05M

Free Cash Flow

FY2025Q1

YoY :

-10.76%

73.50

Gross Profit Margin - %

FY2025Q1

YoY :

+144.92%

13.25

FCF Margin - %

FY2025Q1

YoY :

+111.00%

8.44

Net Margin - %

FY2025Q1

36.79

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

42.5M

USD

3-6

Months

37.9M

USD

6-9

Months

50.0M

USD

0-12

Months

22.8M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

132.3K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 211.82% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

6.0M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

42.5M

USD

3-6

Months

37.9M

USD

6-9

Months

50.0M

USD

0-12

Months

22.8M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

132.3K

USD

Months

0-12

0.0

USD

Months

HIMS News & Events

Events Timeline

2025-07-16 (ET)

2025-07-16

16:42:07

Mixed options sentiment in Hims and Hers Health with shares up 2.49%

2025-07-09 (ET)

2025-07-09

09:57:22

Hims & Hers rallies after announcing plans to enter Canada

2025-06-23 (ET)

2025-06-23

12:53:33

Hims & Hers CEO 'disappointed,' says Novo Nordisk 'misleading the public'

News

4.0

07-26Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

7.0

07-25Globenewswire

HIMS STOCK UPDATE: Hims & Hers Health, Inc. (NYSE:HIMS) is being Sued for Securities Fraud – Contact BFA Law by August 25 Class Action Deadline

7.0

07-25PRnewswire

HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS